Stem cell shot aimed at reversing frailty in seniors
NCT ID NCT06063590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the safety of StromaForte, a stem cell product made from donor bone marrow, in 12 frail adults aged 60 to 85. Participants received a single intravenous infusion of 100 million cells. The main goal was to check for side effects within 28 days, with follow-up for up to 6 months. Researchers also measured changes in inflammation markers like TNF-alpha and CRP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
StromaForte (donor bone marrow stem cells)
What this could lead to
If safe, this could point toward a treatment to reduce frailty in older adults.
What could go wrong
This is a very early, small safety trial with only 12 people. It cannot prove effectiveness, and stem cell infusions carry risks like allergic reactions or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGING FRAILTY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Burjeel Medical City
Abu Dhabi, United Arab Emirates